Apparently it's just plain IR dextroamphetamine sulphate that comes in a greater range of dosage strengths, including 2.5 mg and 7.5 mg, which might be useful for precisely tailoring a low dose to the needs of patients that are either children or strongly responsive to amphetamines.
But as far as pharmacology is concerned, there's zero innovation here.